Skip to content
OpenCapital
Get started
Ultragenyx Pharmaceutical logo

Ultragenyx Pharmaceutical (RARE) Q1 2026 Earnings

RARE·Reported May 5, 2026·After market close

Ultragenyx Pharmaceutical reported Q1 2026 revenue of $136.0M (-2.4% YoY), missed analyst consensus of $158.2M by $22.2M. Diluted EPS came in at $-1.84 (-17.2% YoY), missed the $-1.49 consensus by $0.35.

Revenue
$136.0Mmissed by $22.2M
Consensus: $158.2M
Diluted EPS
$-1.84missed by $0.35
Consensus: $-1.49
SEC

SEC Filings

Earnings release8-K · 0001193125-26-206368
Quarterly report10-Q · 0001193125-26-206960

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Ultragenyx Pharmaceutical's Q1 2026 earnings report.

Ultragenyx Pharmaceutical (RARE) reported Q1 2026 earnings on May 5, 2026 after market close.

Ultragenyx Pharmaceutical reported revenue of $136.0M and diluted EPS of $-1.84 for Q1 2026.

Revenue missed the consensus estimate of $158.2M by $22.2M. EPS missed the consensus estimate of $-1.49 by $0.35.

Compared to the same quarter a year prior, revenue declined 2.4% from $139.3M a year earlier and diluted EPS declined 17.2% from $-1.57.

You can read the 8-K earnings release (0001193125-26-206368) and the 10-Q periodic report (0001193125-26-206960) directly on SEC EDGAR. The filing index links above go to sec.gov.